Environmental Engineering Reference
In-Depth Information
57. Gramatica A, Petazzi RA, Lehmann MJ, Ziomkowska J, Herrmann A, Chiantia S (2014)
ʱ
Env-decorated phosphatidylserine liposomes trigger phagocytosis of HIV-virus-like parti-
cles in macrophages. Nanomedicine pii: S1549-9634(14)00043-4
58. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D (2014) Nanoscale drug delivery
systems and the blood-brain barrier. Int J Nanomedicine 9:795-811. doi:
10.2147/IJN.
59. Sagar V, Pilakka-Kanthikeel S, Pottathil R, Saxena SK, Nair M (2014) Towards
nanomedicines for neuroAIDS. Rev Med Virol 24(2):103-124
60. Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis
VR, Levy JA, Szoka FC Jr (2014) Chemically modified peptides based on the membrane
proximal external region of HIV-1 envelope induce high titer, epitope specific
non-neutralizing antibodies in rabbits. Clin Vaccine Immunol pii: CVI.00320-14
61. Cho H, Stuart JM, Magid R, Danila DC, Hunsaker T, Pinkhassik E, Hasty KA (2014)
Theranostic immunoliposomes for osteoarthritis. Nanomedicine 10(3):619-627. doi:
10.
62. Afzal E, Zakeri S, Keyhanvar P, Bagheri M, Mahjoubi P, Asadian M, Omoomi N,
Dehqanian M, Ghalandarlaki N, Darvishmohammadi T, Farjadian F, Golvajoee MS,
Afzal S, Ghaffari M, Cohan RA, Gravand A, Ardestani MS (2013) Nanolipodendrosome-
loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strat-
egy approaches in muscular dystrophy. Int J Nanomedicine 8:2943-2960. doi:
10.2147/IJN.
63. Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC (2013)
Application of liposomes in drug development—focus on gastroenterological targets. Int J
Nanomedicine 8:1325-1334. doi:
10.2147/IJN.S42153
64. Sun M, Su X, Ding B, He X, Liu X, Yu A, Lou H, Zhai G (2012) Advances in
nanotechnology-based
delivery
systems
for
curcumin. Nanomedicine
(Lond)
7
(7):1085-1100. doi:
10.2217/nnm.12.80
65. Kozako T, Arima N, Yoshimitsu M, Honda SI, Soeda S (2012) Liposomes and nanotechnol-
ogy in drug development: focus on oncotargets. Int J Nanomedicine 7:4943-4951. doi:
10.
66. Agrati C, Marianecci C, Sennato S, Carafa M, Bordoni V, Cimini E, Tempestilli M, Pucillo
LP, Turchi F, Martini F, Borioni G, Bordi F (2011) Multicompartment vectors as novel drug
delivery systems: selective activation of T
lymphocytes after zoledronic acid delivery.
Nanomedicine 7(2):153-161. doi:
10.1016/j.nano.2010.10.003
67. Campani V, Marchese D, Pitaro MT, Pitaro M, Grieco P, De Rosa G (2014) Development of a
liposome-based formulation for vitamin K1 nebulization on the skin. Int J Nanomedicine.
doi:
10.2147/IJN.S58365
68. Mota Ade C, de Freitas ZM, Ricci J´nior E, Dellamora-Ortiz GM, Santos-Oliveira R, Ozzetti
RA, Vergnanini AL, Ribeiro VL, Silva RS, dos Santos EP (2013) In vivo and in vitro
evaluation of octyl methoxycinnamate liposomes.
ʳʴ
Int J Nanomedicine 8:4689-4701.
doi:
10.2147/IJN.S51383
69. Vyas A, Kumar Sonker A, Gidwani B (2014) Carrier-based drug delivery system for
treatment of acne. Scientific World Journal 2014:276260. doi:
10.1155/2014/276260
70. Zhou Y, Ning Q, Yu DN, Li WG, Deng J (2014) Improved oral bioavailability of
breviscapine via a Pluronic P85-modified liposomal delivery system. J Pharm Pharmacol
66:903-911. doi:
10.1111/jphp.12215
71. Migliore MM, Ortiz R, Dye S, Campbell RB, Amiji MM, Waszczak BL (2014) Neurotrophic
and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson
'
s disease.
Neuroscience pii: S0306-4522(14)00411-4. doi:
10.1016/j.neuroscience.2014.05.019
72. Yamada Y, Tabata M, Yasuzaki Y, Nomura M, Shibata A, Ibayashi Y, Taniguchi Y, Sasaki S,
Harashima H (2014) A nanocarrier system for the delivery of nucleic acids targeted to a
pancreatic beta cell line. Biomaterials 35(24):6430-6438. doi:
10.1016/j.biomaterials.2014.
